Trial Profile
Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. A 12-week, randomized, double-blind, active (fluoxetine 10 mg/day with potential adjustment to 20 mg/day) and placebo-controlled, parallel groups, international, multicentre study followed by an optional open-labelled 21-month safety extension period
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors IRIS
- 28 Jun 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 19 Feb 2021 This trial has been completed in Finland according to European Clinical Trials Database record.
- 26 Sep 2020 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.